LS

Lite Strategy, Inc.

LITS·NASDAQ

$1.43

-3.5%
HealthcareBiotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$52.60M
EPS-2.3900
P/E Ratio-1.89
Earnings Date02/11/2026

lits

Other Current Liabilities

Last Annual Value

305.00K

3-Year CAGR

-59%

5-Year CAGR

-43%

10-Year CAGR

-24%

LS

Lite Strategy, Inc. Competitors Analysis of Other Current Liabilities

LITS · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
305.00K
-65.1%-42.6%N/A 
4.86M
-5.1%24.3%25.2%
10.29M
20.3%21.3%N/A
12.21M
46.8%78.9%N/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
5.00M
33.1%57.3%N/A
12.53M
23.8%20.1%N/A
18.44M
12.0%N/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-2.98M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
13.61M
25.2%27.6%-12.1%
7.86M
20.4%15.7%N/A
33.64M
110.1%190.4%N/A
LS

Lite Strategy, Inc. Fair Value Envelope

LITS · NASDAQ

Our analysis suggests that LITS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.43, this represents a potential HIDDEN relative to our calculated worth for Lite Strategy, Inc..

Intrinsic Value
Current Price: $1.43